What if the immune system could be powered up to fight cancer?
Obsidian is developing next-generation cell and gene therapies with pharmacologic operating systems

About Obsidian

Obsidian Therapeutics, founded in 2015, aspires to extend adoptive immunotherapy to every patient with cancer. We do this by building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients.  MORE >

News

12/06/2017

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

MORE >

Careers

Principal Scientist/Associate Director: Immuno-Oncology Pharmacology

MORE >

Scientist / Sr Scientist: Lentivirus production

MORE >

Senior Scientist: Discovery

MORE >

Science

Overview

Obsidian Therapeutics is developing a suite of technologies that allow for exquisite control of protein activity in cells, thereby enabling tunable cell and gene therapies. These technologies will enable the creation of a powerful new class of therapies that address the safety and efficacy limitations  MORE >

Advancing the Platform

Obsidian has taken the original work on destabilizing domains (DDs) performed by our scientific founder, Professor Thomas Wandless, and has substantially advanced the platform. We have created libraries of novel DDs with properties that make  MORE >

Michael Gilman, PhD

Chief Executive Officer

Michael Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. Mike currently serves as an Advisor at Atlas Venture and on the Boards of Directors of Scholar Rock,  MORE >

Tariq Kassum, MD

Senior Vice President and Head of Business Operations

Tariq Kassum is Head of Business Operations at Obsidian Therapeutics and was a member of the company’s founding team. Previously he was Vice President, Business Development and Strategy, for Takeda Oncology,  MORE >

Steve Shamah, PhD

Senior Vice President and Head of Research

Steve Shamah joined Obsidian Therapeutics in September 2016 as Senior Vice President and Head of Research where he leads a dynamic team towards the discovery and development of next generation cell  MORE >

Vipin Suri, PhD

Vice President, Discovery

Vipin Suri is the VP of Discovery at Obsidian Therapeutics and joined Obsidian’s founding team in January of 2016. Prior to Joining Obsidian, Vipin was Head of Biology at Raze Therapeutics  MORE >

Celeste Richardson, PhD

Vice President, Cell Therapy

Celeste Richardson joined Obsidian Therapeutics in November of 2016 as Vice President of Cell Therapy.  Prior to joining Obsidian, Celeste was at the Novartis Institutes for Biomedical Research where she led  MORE >

Mike Briskin, PhD

Senior Advisor, Research

Mike Briskin is Senior Advisor at Obsidian Therapeutics.Dr. Briskin brings more than 20 years of industry experience in multiple areas of drug discovery, including molecular biology, immunobiology, oncology and inflammation. Prior to  MORE >

Peter Barrett, PhD

Chairman

Peter Barrett is a partner at Atlas Venture and focuses on investments in therapeutics that significantly improve patients’ quality of life.

At Atlas, Peter has been involved in  MORE >

Jason Gardner, D.Phil

Jason Gardner is Chief Executive Officer and Cofounder of Magenta Therapeutics. He has more than 20 years of experience in stem cell science and industry leadership roles. He worked at  MORE >

Karen Hong, PhD

Karen Hong is Senior Investment Director at Takeda Ventures Incorporated. Prior to Takeda Ventures, Dr. Hong was a Partner at ProQuest Investments, a healthcare dedicated venture fund, where she worked for  MORE >

Carolyn Ng, PhD

Carolyn Ng is a Principal of Vertex Ventures HC, the venture capital arm of Temasek Holdings specializing in early stage life sciences investments globally. At Vertex, Carolyn is responsible for  MORE >

Michael Gilman, PhD

Michael Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. Mike currently serves as an Advisor at Atlas Venture and on the Boards of Directors of Scholar Rock,  MORE >

Careers

Principal Scientist/Associate Director: Immuno-Oncology Pharmacology

MORE >

Scientist / Sr Scientist: Lentivirus production

MORE >

Senior Scientist: Discovery

MORE >

Associate Scientist/Scientist: Immunology Pharmacology

MORE >

Research Associate/Sr. Research Associate: Immuno-Oncology Pharmacology

MORE >

Contact

Obsidian Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge MA, 02138
info@obsidiantx.com